What is intracerebral haemorrhage and how common is it in Australia?

Intracerebral haemorrhage (ICH) is a type of stroke caused by bleeding directly into the brain tissue. It accounts for approximately 10–15% of all strokes in Australia and carries a higher short-term mortality than ischaemic stroke (blockage-type stroke). Survivors face a significant risk of recurrent stroke — both haemorrhagic and ischaemic — and high blood pressure is the most important modifiable risk factor for recurrence. The Stroke Foundation of Australia estimates that about 56,000 Australians have a stroke each year.

Does this study mean my GP should lower my blood pressure target?

Not necessarily, and not yet. This meta-analysis is a very strong signal — four randomised controlled trials, nearly 3,000 patients, a clinically meaningful result — but it will need to be reviewed by guidelines bodies before it changes routine clinical recommendations. It is most directly relevant if you have survived an ICH specifically, rather than an ischaemic stroke or a different cardiovascular event. The right response is to discuss the findings with your GP or specialist, particularly if your current blood pressure management leaves room to push further without causing side effects. Australian guidelines for post-stroke blood pressure management are produced by the Stroke Foundation.

Intensive BP control cuts recurrent stroke by 38% after brain bleed

What just happened

Researchers from The George Institute for Global Health have published a meta-analysis in The Lancet Neurology showing that intensive long-term blood pressure control reduces the risk of recurrent stroke by 38% in people who have survived an intracerebral haemorrhage (ICH) — a brain bleed.

The study pooled data from 2,944 adults across four randomised controlled trials. The intensive treatment group achieved an average systolic blood pressure of 127 mmHg, compared to 138 mmHg in the standard care group — a difference of just over 11 points. That modest reduction in blood pressure translated to a striking reduction in recurrent stroke: from 10.4% in the standard group to 6.5% in the intensive group. The reduction in haemorrhagic stroke specifically was even more dramatic — 61% lower in the intensively treated group.

Importantly: there was no increase in serious adverse events. The intensive group had a 29% rate of serious adverse events versus 33% in the control group — suggesting that more aggressive blood pressure treatment was not causing meaningful harm.

Both-and

Why the finding is more significant than the headline number

A 38% reduction in recurrent stroke is a clinically meaningful number. But the detail that makes this study particularly important is this: the benefit held even for patients who were already at or below current guideline targets.

Current Australian guidelines for blood pressure management after stroke recommend a target below 130/80 mmHg systolic for most patients. This analysis found that patients who were already meeting that target — already below 130 mmHg systolic — still derived benefit from pushing further toward the 127 mmHg achieved in the intensive group. That is a challenging finding for the guideline framework: it suggests the threshold set as “good enough” may not be “good enough” for ICH survivors specifically.

Professor Craig Anderson, the study’s lead author, noted that “preventing stroke recurrence requires us to address persistent barriers to blood pressure control.” The barriers he is referring to are not just clinical. They include medication adherence, the challenge of sustaining aggressive treatment long-term, and the fact that many patients with complex vascular histories are managing multiple competing health priorities. Achieving and maintaining 127 mmHg systolic as a long-term target requires sustained clinical partnership — not a one-off adjustment.

The distinction between ICH and ischaemic stroke

It is worth being precise about what this study does and does not tell us. Intracerebral haemorrhage accounts for approximately 10–15% of all strokes in Australia — it is less common than the more familiar blockage-type (ischaemic) stroke. The populations differ in important ways, including in the downstream bleeding risk profile of intensive blood pressure treatment.

This meta-analysis pooled evidence specifically from ICH survivors. Whether the same intensive target benefit applies to people who have survived an ischaemic stroke — or who have never had a stroke but have high cardiovascular risk — is a separate question that this study does not answer. The findings are most directly actionable for people who have survived a brain haemorrhage and are currently being managed for secondary prevention.

For the broader population of people with hypertension — which in Australia includes approximately one-third of adults — the study reinforces what is already known: blood pressure is the most powerful modifiable cardiovascular risk factor, and the lower the sustained treated level, the lower the risk. But “lower is universally better” is not the conclusion: intensive targets bring their own risks, including symptomatic low blood pressure, falls, and in some populations, renal effects. Clinical decisions about individual targets depend on the whole person.

What it means for the guideline landscape

This meta-analysis represents the highest-quality evidence that intensive blood pressure management after ICH produces significant benefit beyond current targets. The Stroke Foundation’s clinical guidelines are a living document and will need to consider this evidence in their next update cycle. The George Institute is one of the world’s leading cardiovascular research centres, and The Lancet Neurology is a high-prestige peer-reviewed journal — the evidence quality is not in question.

Whether the findings change practice in the short term depends on specialist neurology and stroke medicine communities digesting the data and on whether existing guideline groups move their recommended thresholds. Guideline change typically follows evidence by 12–36 months in Australia. In the interim, the evidence is available to treating clinicians who choose to act on it.

My two cents

If you have survived a brain haemorrhage and are now being managed for blood pressure in general practice, this is the paper your GP or neurologist should know about. The core question it raises is whether your current target — even if you’re meeting guideline recommendations — is optimal for you, given the evidence that ICH survivors appear to benefit from pushing further.

That is not a call to self-adjust medications. It is a call for a structured conversation. The evidence now suggests that “within guidelines” may not be the ceiling worth aiming for in this population. The George Institute’s researchers are clear that the treatment was safe — no increase in serious adverse events despite lower targets — which removes one of the standard reasons to stop at conventional thresholds.

For everyone else: blood pressure remains the most actionable cardiovascular risk factor in general practice. If you have not had your blood pressure checked recently, or if it’s been running higher than 130/80 mmHg and you haven’t had a structured review, that is the thread worth pulling — independent of this particular study.

Verdict: yes — strong evidence, high-quality source, and a finding that directly challenges current secondary prevention targets for a specific high-risk group.

Sources cited

Intensive blood pressure-lowering cut recurrent stroke risk by around 38% after brain haemorrhage. The George Institute for Global Health, 13 August 2026. https://www.georgeinstitute.org/news-and-media/news/intensive-blood-pressure-lowering-cut-recurrent-stroke-risk-by-around-38-after-brain-haemorrhage
Clinical guidelines for stroke management. Stroke Foundation of Australia. https://informme.org.au/guidelines/living-clinical-guidelines-for-stroke-management
Blood pressure lowering after intracerebral haemorrhage: systematic review and meta-analysis. The Lancet Neurology, 2026. https://www.thelancet.com/journals/laneur/home